Screen Shot 2020-09-16 at 1.45.20 PM.png

Prothelia is a preclinical-stage biopharmaceutical company focused on the development of novel therapeutic proteins to treat rare muscle diseases with extremely high unmet need.

Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.